Based on the Beigene Ltd stock forecast from 0 analysts, the average analyst target price for Beigene Ltd is not available over the next 12 months. Beigene Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Beigene Ltd is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, Beigene Ltd’s stock price was HKD 145.70. Beigene Ltd’s stock price has changed by -2.41% over the past week, +23.16% over the past month and +35.53% over the last year.
No recent analyst target price found for Beigene Ltd
No recent average analyst rating found for Beigene Ltd
Company Overview Beigene Ltd
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands. Read Less
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) ...Read More
Frequently Asked Questions About Beigene Ltd (6160:HK) Stock
Stock Target Advisor's fundamental analysis for Beigene Ltd's stock is Neutral.
Unfortunately we do not have enough data on 6160:HK's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 6160:HK's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 6160:HK's stock to indicate if its overvalued.
The last closing price of 6160:HK's stock was HKD 145.70.
The most recent market capitalization for 6160:HK is HKD 206.43B.
Unfortunately we do not have enough analyst data on 6160:HK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Beigene Ltd's stock.
As per our most recent records Beigene Ltd has 10,000 Employees.
Beigene Ltd's registered address is 94 Solaris Avenue, Camana Bay, Cayman Islands, KY1-1108.
You can get more information about it from Beigene Ltd's website at https://www.beigene.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Beigene Ltd (6160:HK) Stock
Stock Target Advisor's fundamental analysis for Beigene Ltd's stock is Neutral.
Unfortunately we do not have enough data on 6160:HK's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 6160:HK's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 6160:HK's stock to indicate if its overvalued.
The last closing price of 6160:HK's stock was HKD 145.70.
The most recent market capitalization for 6160:HK is HKD 206.43B.
Unfortunately we do not have enough analyst data on 6160:HK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Beigene Ltd's stock.
As per our most recent records Beigene Ltd has 10,000 Employees.
Beigene Ltd's registered address is 94 Solaris Avenue, Camana Bay, Cayman Islands, KY1-1108.
You can get more information about it from Beigene Ltd's website at https://www.beigene.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 6160:HK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Join over half-million smart investors across the world
Loading...
The Adjusted Closing and Unadjusted Closing sections display stock prices with and without adjustments, respectively. The Share Trading Volume section shows the stocks trading volume over time, indicating market activity. The Compare Performance section allows you to analyze a stocks performance against others by entering symbols and clicking Add to see relative returns. These tools aid in making informed investment decisions. Use the date range selectors to view trends from the past month (1m), three months (3m), six months (6m), year-to-date (YTD), one year (1y), five years (5y), or all available data (All).
